Cimzia: new TNF-alpha inhibitor

Cimzia is a new addition to the management of moderate to severely active rheumatoid arthritis in combination with methotrexate or as monotherapy.

PHARMACOLOGY

Certolizumab pegol is a PEGylated formulation of a humanized monoclonal antibody specific for tnf-α.

CLINICAL STUDIES

In two studies comparing the use of certolizumab and MTX to placebo and MTX, significantly more patients in the certolizumab groups achieved the American College of Rheumatology 20 per cent criteria for improvement (ACR20) at 24 weeks.1,2

The most common adverse effects in the trials were headache, hypertension, UTI, URTI and back pain.1,2

View Cimzia drug record

REFERENCES

  1. Keystone E et al. Arthritis Rheumatism 2008; 58:3319-29.
  2. Smolen J et al. Ann Rheum Dis 2009; 68:797-804.

Further information: UCB

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Third tiotropium inhaler adds to treatment options for COPD patients

Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...